PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6:		(11) International Publication Number: WO 99/29331
A61K 35/78, 31/35	A1	(43) International Publication Date: 17 June 1999 (17.06.99)
(21) International Application Number: PCT/EP (22) International Filing Date: 30 November 1998 ((30) Priority Data: MI97A002690 4 December 1997 (04.12.97 (71) Applicant (for all designated States except US): S.P.A. [IT/IT]; Viale Ortles, 12, I-20139 Milano ((72) Inventors; and (75) Inventors/Applicants (for US only): MORAZZON [IT/IT]; Viale Ortles, 12, I-20139 Milano (IT BARDELLI, Ezio [IT/IT]; Via Val di Sole, 22, Milano (IT). (74) Agent: MINOJA, Fabrizio; Bianchetti Bracco Minoja Rossini, 8, I-20122 Milano (IT).	30.11.9 INDEN (IT). NI, Pac). BOI , I–201	BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of
AGENTS (57) Abstract		EXTRACTS OF VITIS VINIFERA AS ANTI-ATHEROSCLEROTIC useful for the prevention and the treatment of atherosclerotic pathological

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

l	AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
	AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
	AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
١	AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
l	AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
ı	BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
l	BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
1	BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
ı	BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
ı	BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
١	BJ	Benin	IB	Ireland	MN	Mongolia	UA	Ukraine
l	BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
١	BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
ļ	CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
l	CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
l	CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
l	СН	Switzerland	KG	Kyrgyzstan	NO	Norway	zw	Zimbabwe
l	CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
İ	CM	Cameroon		Republic of Korea	PL	Poland		
ı	CN	China	KR	Republic of Korea	PT	Portugal		
ı	CU	Cuba	KZ	Kazakstan	RO	Romania		
۱	cz	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
١	DE	Germany	L	Liechtenstein	SD	Sudan		
١	DK	Denmark	LK	Sri Lanka	SE	Sweden		
۱	EE	Estonia	LR	Liberia	SG	Singapore		
ı								

THE USE OF PHOSPHOLIPID COMPLEXES OF EXTRACTS OF VITIS VINIFERA AS ANTI-ATHEROSCLEROTIC AGENTS

The present invention relates to the use of phospholipid complexes of oligomeric proanthocyanidins containing from 2 to 7 catechin units extracted from Vitis vinifera for the preparation of medicaments for the treatment and the prophylaxis of atherosclerosis, and of miocardiac and cerebral infarctions.

The extracts of *Vitis vinifera* are already known and used in the therapy of cardiovascular disorders connected with venous insufficiency, in the treatment of impaired conditions of capillary permeability and resistance and in cicatrization. These extracts, which can be obtained from the seeds of the plant as described in GB-A-1,541,469 or in FR-A-2,092,743, are a mixture of polyphenols such as epicatechin and its polymerization products, in part esterified at the C-3 hydroxyl of the monomer with gallic acid. The phospholipid complexes of the extracts of *Vitis vinifera* are described in US-4,963,527 and are at present commercially available under the trade mark Leucoselect.

10

15

20

It has now surprisingly been found that the complexes prepared according to US-4,963,527 exert, when administered systemically, preferably by the oral route, a marked anti-atherosclerotic activity both in animals and in humans.

25 More specifically, it has been found that the phospholipid complexes of oligomeric proanthocyanidins containing from 2 to 7 catechin units extracted from Vitis vinifera, prevent or reduce the formation of athero-

2

sclerotic plaques in a dose-depending relationship.

5

10

15

20

25

30

Such an activity was evidenced in rabbits fed with hypercholesterolemic diet, so as to induce atherosclerotic lesions similar to the human ones at the vascular level, particularly at the aortic arch, ventral aorta, carotids and cerebral vessels. In said model, the above mentioned phospholipid complexes change the macro and microscopical vascular condition reducing, compared with untreated animals, both the number of atheromatous plaques and their severity, with a surprising vasculartissular benefit. In another atherosclerosis model, with the purpose of cerebral protection, wherein the vasal lumen of rabbit internal carotid had been surgically reduced, while administering a hypercholesterolemic diet fats, a decrease in saturated obstruction, a reduction of vessel walls thickness and an increased survival of the animals were evidenced. Furthermore, in atherosclerotic patients, a reduction in carotid obstruction due to atheromatous plaques and an Doppler flow, evaluated by improved carotid ultrasonography, were observed.

The phospholipid complexes of the proanthocyanidins extracted from *Vitis vinifera* can be used in suitable oral formulations, such as tablets, soft— or hard-gelatin capsules, at dosages ranging from 50 to 500 mg two-three times a day, depending on the severity of the disease to treat. The preparation of the pharmaceutical formulations can be carried out according to conventional techniques and excipients.

The following examples illustrate the invention in greater detail.

3 Example 1

3 groups of 8 New Zealand rabbits each, were treated as follows:

Group 1): Control, normal diet

5 Group 2): Hypercholesterolemic diet (0.2% cholesterol)

Group 3): Hypercholesterolemic diet + phospholipid complex of extracts of Vitis vinifera (0.2% cholesterol + 2% Leucoselect(R)).

After 8 weeks, during which cholesterol, LDL/VLDL,

10 HDL and triglycerids levels were measured, the animals were killed.

The number, the size and the distribution of the atherosclerotic lesions on thoracic and abdominal aorta were evaluated.

Aorta strips were fixed and stained with Sudan IV to visualize the lesions and to evaluate the vasal cholesterol and the content in oxidized cholesterol by gaschromatography.

The results reported in the following table prove

that the treatment with phospholipid complexes of
extracts of Vitis vinifera decreases in a statistically
significant way the atherosclerotic lesions induced by
hypercholesterolemic diet.

Table

Treatment	area percent of the lesion
Group 1	1%
Group 2	27%
Group 3	5%*
	Group 1 Group 2

^{*}p<0.01 compared with group 2

4 Rxample 2

	<u>Example 2</u>		
	Capsules containing 500 mg of phospholipi	d complex	of
	extracts of Vitis vinifera		
	Composition:		
5	Complex of extract of Vitis vinifera		
	with soy phosphatidylcholine	200	mg
	Lactose	57	mg
	Modified starch	40	mg
	Magnesium stearate	3,0	mg
10	Example 3		
	Gastro-resistant tablets		
	Complex of extract of Vitis vinifera	0.50	
	with soy phosphatidylcholine		mg
	Microcrystalline cellulose		mg
15	Precipitated silica		mg
	Magnesium stearate	4	1 mg
	Methacrylic acid anionic		
	polymer and esters thereof		2 mg
	Talc	-	8 mg
20	Magnesium carbonate		8 .mg
	Maize star		5 mg
	Gum arabic	15	9 mg
	Example 4		
	Soft-gelatin capsules		
25	Complex of extract of Vitis vinifera		
	with soy phosphatidylcholine		6 mg
	Peanut oil		9 mg
	Partially hydrogenated vegetable oils	10)0 mg
	Soy lecithin		5 mg

5

CLAIMS

5

20

- 1. The use of phospholipid complexes of oligomeric proanthocyanidins containing from 2 to 7 catechin units extracted from *Vitis vinifera* for the preparation of medicaments for the therapeutical and prophylactic treatment of atherosclerosis and of miocardiac and cerebral infarctions.
- The use as claimed in claim 1, wherein the unitary
 dosage of the medicament ranges from 50 to 500 mg of active ingredient.
 - 3. The use as claimed in claim 1 or 2, wherein the medicament is administrable orally.
- The use as claimed in claim 3, wherein the
 medicament is in the form of soft- or hard- gelatin capsules or of tablets.
 - 5. A method for the treatment of atherosclerosis and of miocardiac and cerebral infarctions, which comprises administering a patient with an effective amount of a phospholipid complex of extract of *Vitis vinifera*.

Interi Aai Application No PCT/EP 98/07662

			FC1/EF 36/0/002
A. CLASSIF IPC 6	A61K35/78 A61K31/35		
According to	International Patent Classification (IPC) or to both national class	fication and IPC	
B. FIELDS	SEARCHED		
IPC 6	cumentation searched (classification system followed by classific $A61K$		
	ion searched other than minimum documentation to the extent the		
Electronic de	ata base consulted during the International search (name of data	base and, where practical	, search (erms useg)
C. DOCUME	ENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the	relevant passages	Relevant to claim No.
x	US 4 963 527 A (BOMBARDELLI EZI 16 October 1990 cited in the application see column 2, line 38 - line 63		1-5
X	EP 0 713 706 A (SUNTORY LTD) 29 see page 3, line 28 - page 4, l	9 May 1996 line 50	1
A	K. TEBIB ET AL.: "ANTIOXYDANT DIETARY POLYMERIC GRAPE SEED TATISSUES OF RATS FED A HIGH CHOLESTEROL-VITAMIN E -DEFICIENT FOOD CHEMISTRY, vol. 59, no. 1, 1997, pages 13! XP002098281	ANNINS IN NT DIET"	•
		-/	
X Fur	ther documents are listed in the continuation of box C.	X Patent famil	y members are listed in annex.
* Special c	ategories of cited documents :	"T" later document pu	iblished after the international filing date and not in conflict with the application but
"E" earlier filling		cited to understa Invention "X" document of particannot be consi	and the principle or theory underlying the cular relevance; the claimed invention dered novel or cannot be considered to
which citation "O" docum	nent which may throw doubts on priority claim(s) or h is cited to establish the publication date of another on or other special reason (as specified) ment referring to an oral disclosure, use, exhibition or r means	"Y" document of part cannot be consi document is cor	tive step when the document is taken alone icular relevance; the claimed invention dered to involve an inventive step when the hished with one or more other such docu- mbination being obvious to a person skilled
"P" docum	nent published prior to the international filing date but than the priority date claimed	in the art. "&" document memb	er of the same patent family
Date of the	e actual completion of the international search		t the international search report
	29 March 1999	13/04/	
Name and	t mailing address of the ISA European Patent Office, P.B. 5818 Patentiaan 2 NL - 2280 HV Rijswijk Tu 21 551 200 pl	Authorized office	
1	Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Rempp,	, G

1

Interr nal Application No PCT/EP 98/07662

	ion) DOCUMENTS CONSIDERED TO BE RELEVANT	Relevant to claim No.
ategory *	Citation of document, with indication, where appropriate, of the relevant passages	nelevant to claim No.
	E. BOMBARDELLI ET AL.: "BIOLOGICAL ACTIVITY OF PROCYANIDINS FROM VITIS VINIFERA L." BIOFACTORS, vol. 6, no. 4, 1997, pages 429-431, XP002098282	
	·	
		·
	·	

1

In.c. national application No.
PCT/EP 98/07662

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
Claims Nos.: Secause they relate to subject matter not required to be searched by this Authority, namely: See FURTHER INFORMATION SHEET PCT/ISA/210
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II Observations where unity of Invention is lacking (Continuation of Item 2 of first sheet)
This International Searching Authority found multiple inventions in this international application, as follows:
As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this international Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark on Protest The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Although claim 5 IS directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Claims Nos.: 5

Rule 39.1(1v) PCT - Method for treatment of the human or animal body by therapy

information on patent family members

Inter: nal Application No
PCT/EP 98/07662

Patent document cited in search report		Publication date		atent family member(s)	Publication date
US 4963527	Α	16-10-1990	AT	91688 T	15-08-1993
			CA	1337604 A	21-11-1995
			DE	3882383 A	26-08-1993
			DE	3882383 ·T	11-11-1993
			EP	0275224 A	20-07-1988
			ĒS	2056943 T	16-10-1994
			JP	1013031 A	17-01-1989
			JP	1954097 C	28-07-1995
			JP	6076335 B	28-09-1994
			PT	86509 B	31-12-1991
FP 0713706		29-05-1996	F I	955691 A	29-05-1996
E1 0/13/00	^	LJ 03 1330	JP	8225453 A	03-09-1996
			NO	954834 A	29-05-1996
			ÜS	5607965 A	04-03-1997